The gene therapy market is surging toward $36.55 billion by 2032, powered by rising demand for curative treatments that target genetic diseases at their source([1]) . The FDA approved three ...

The use of bispecific antibodies (BsAb) before chimeric antigen receptor T-cell therapy (CAR-T) appeared to be a more optimal ...

Histological analysis of the resected specimen diagnosed a Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) with mild lymphocytic submucosal inflammation. Crucially, there was no ...

“I can’t help but notice we are in a Whole Foods,” I tell a Whole Foods employee who—perhaps having noticed me walking around ...

Pandorum Technologies, a clinical-stage regenerative medicine company building a next-generation platform for programmable tissue regeneration, today announced a strategic collaboration with Hyderabad ...

BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) ...

Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with ...

MarketsandMarkets forecasts the sector will expand at 38.6% annually through 2030 [3], driven by chronic disease burden and data explosion. The FDA cleared over 1,250 AI-enabled medical devices by mid ...

Cutting calories has long been linked to longer life in lab animals, but scientists are now tracing that effect down to the ...

The market is repricing risk around a single variable: detection. The most dangerous threats are the ones that cannot be seen. Hidden cardiac defects collapsing athletes. Tumors camouflaged in healthy ...

Study Links Mediterranean Diet to Lower Multiple Sclerosis Risk Levels Eating your way to brain health might be simpler than ...